In a report issued on November 28, Konstantinos Aprilakis from JMP Securities reiterated a Buy rating on Evelo Biosciences Inc (EVLO), with a price target of $25. The company’s shares closed on Friday at $9.92.
According to TipRanks.com, Aprilakis is ranked 0 out of 5 stars with an average return of -19.1% and a 19.6% success rate. Aprilakis covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Karyopharm Therapeutics, and Syros Pharmaceuticals.
Currently, the analyst consensus on Evelo Biosciences Inc is a Moderate Buy with an average price target of $25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.75 and a one-year low of $6.51. Currently, Evelo Biosciences Inc has an average volume of 29.68K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evelo Biosciences, Inc. engages in the development of pharmaceutical compositions of specific strains of naturally-occurring microbes. Its product candidates are orally delivered and are intended to modulate systemic immunology and biology through direct interactions with human cells in the gut.
